Pembrolizumab, a humanized immunoglobulin G4 monoclonal antibody against human programmed cell death-1 (PD-1), activates tumor-specific cytotoxic T cells by inhibiting the binding of PD-1 to its ligands [4]. The gene discussed is PDCD1; the disease is neoplasm.